Literature DB >> 28321373

A Review of Skull Base Tumor Clinical Trials: Past Trends and Future Opportunities.

Anand Devaiah1, Charles Murchison2.   

Abstract

Objective Tumors of the anterior and lateral skull base (TALSB) are relatively rare but can be devastating to patients. By examining trials focused on TALSB, we can characterize the studies that predominate and better understand current directions of study. This gives us a better understanding of future studies to pursue. Study Design This is a retrospective analysis. Settings We set skull base tumor clinical trials in the United States which are listed in ClinicalTrials.gov. Subjects and Methods We used the information available on ClinicalTrials.gov to identify trends in clinical trials studying sinonasal/anterior skull base (SNASB) tumors, vestibular schwannoma (VS), and pituitary tumors. The publication rate for these trials was examined using PubMed.gov. Results Of the 71 trials analyzed, 83% investigated treatments for pituitary tumors, 16% for VSs, and 1% for SNASB tumors. Drug studies comprised 90% of all trials, while 9% included radiation therapy in their treatment and 10% included and surgical component. Overall, 64% had their results published in a peer-reviewed journal. Conclusion Among TALSB clinical trials we analyzed, they are weighted heavily toward drug trials. Radiation therapy and surgery, common treatment modalities, are underrepresented in clinical trials. There is a gap between the trials conducted and the rate of reporting, with an emphasis on positive results.

Entities:  

Keywords:  ClinicalTrials.gov; clinical trials; pituitary tumor; sinonasal cancer; skull base tumor; vestibular schwannoma

Year:  2016        PMID: 28321373      PMCID: PMC5357226          DOI: 10.1055/s-0036-1586759

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  14 in total

1.  Recognizing, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the WHO.

Authors:  Kay Dickersin; Iain Chalmers
Journal:  J R Soc Med       Date:  2011-12       Impact factor: 5.344

2.  The existence of publication bias and risk factors for its occurrence.

Authors:  K Dickersin
Journal:  JAMA       Date:  1990-03-09       Impact factor: 56.272

3.  Publication bias: evidence of delayed publication in a cohort study of clinical research projects.

Authors:  J M Stern; R J Simes
Journal:  BMJ       Date:  1997-09-13

4.  Characteristics of NIH- and industry-sponsored head and neck cancer clinical trials.

Authors:  Anand Devaiah; Charles Murchison
Journal:  Laryngoscope       Date:  2016-03-24       Impact factor: 3.325

5.  NIH clinical trials and publication bias.

Authors:  K Dickersin; Y I Min
Journal:  Online J Curr Clin Trials       Date:  1993-04-28

6.  Demographic differences in incidence for pituitary adenoma.

Authors:  Bradley D McDowell; Robert B Wallace; Ryan M Carnahan; Elizabeth A Chrischilles; Charles F Lynch; Janet A Schlechte
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

7.  Analysis of 473 US Head and Neck Cancer Trials (1996-2014): Trends, Gaps, and Opportunities.

Authors:  Anand Devaiah; Charles Murchison
Journal:  Otolaryngol Head Neck Surg       Date:  2015-11-17       Impact factor: 3.497

8.  Vestibular schwannoma surgery outcomes: our multidisciplinary experience in 400 cases over 17 years.

Authors:  Vincent Darrouzet; Jacques Martel; Véronique Enée; Jean-Pierre Bébéar; Jean Guérin
Journal:  Laryngoscope       Date:  2004-04       Impact factor: 3.325

9.  Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis.

Authors:  Joseph S Ross; Tony Tse; Deborah A Zarin; Hui Xu; Lei Zhou; Harlan M Krumholz
Journal:  BMJ       Date:  2012-01-03

10.  Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.

Authors:  Joseph S Ross; Gregory K Mulvey; Elizabeth M Hines; Steven E Nissen; Harlan M Krumholz
Journal:  PLoS Med       Date:  2009-09-08       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.